Kura Oncology Inc

Kura Oncology has launched Caspian Therapeutics, a separately financed company focused on developing menin inhibitors for diabetes and cardiometabolic diseases, backed by a $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, and others. Caspian's lead compound, KO-7246, has shown in preclinical studies to selectively expand pancreatic beta cells, increase endogenous insulin production, and improve glycemic control in models of Type 1 and Type 2 diabetes, with data selected for an oral presentation at the EASD Annual Meeting on September 29, 2026. Kura will retain approximately half ownership of Caspian on a fully diluted basis and board representation, while Caspian operates with dedicated leadership and external capital. Robert Spencer has been appointed President and Chief Operating Officer of Caspian, and the company plans to submit an investigational new drug application for KO-7246 as soon as practicable.

Shares of DICK'S Sporting Goods plummeted 30.7% after the company reported second-quarter fiscal 2026 earnings of $3.53 per share, missing the Zacks Consensus Estimate of $3.78 per share. In contrast, Kura Oncology's shares jumped 9.6% after CEO Troy Wilson revealed in a regulatory filing that he was buying nearly 100,000 shares of common stock. Navitas Semiconductor gained 1.7% after announcing a deal to acquire Claros for $232.8 million in cash and stock. Walmart's shares declined 1% amid a broader retail decline.

Kura Oncology President, Chairman, and CEO Troy Edward Wilson purchased approximately 100,000 shares of the company's common stock on August 24, 2026, according to an SEC Form 4 filing. The transaction was valued at $1.2 million, based on a weighted average purchase price of $12.39 per share. Following the purchase, Wilson's total beneficial ownership stands at roughly 1.2 million shares, an increase of 9%, with about 435,000 shares held directly and 779,000 held indirectly through the One Fish Two Fish Revocable Trust and the Lorax Charitable Remainder Unitrust. The insider buy comes as the clinical-stage biopharmaceutical company reports trailing twelve-month revenue of $77.2 million and a net loss of $296.8 million, with a market capitalization of $1.1 billion. Wilson has led the company since its founding in 2015, and the purchase is seen as a bullish signal given that insiders typically buy only when they expect the share price to rise.

Dick's Sporting Goods shares plunged more than 27% after the retailer reported revenue of $5.59 billion, below the $5.65 billion expected by analysts polled by LSEG, citing a challenging footwear market. Dynatrace rose 3% after Morgan Stanley upgraded it to overweight, while Shift4 Payments gained nearly 4% on a Wells Fargo upgrade to overweight. Moderna rallied 13% after Wolfe Research upgraded it to peer perform, and Marvell Technology jumped 5% after Susquehanna and Rosenblatt raised price targets. Advanced Micro Devices gained 5% after Raymond James upgraded it to strong buy with a $641 price target, and Kura Oncology climbed almost 10% after its CEO disclosed buying 100,000 shares. Navitas Semiconductor rose 5% after announcing a $232.8 million deal to acquire Claros.